Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma

Irene M. Ghobrial, Chia Jen Liu, Oksana Zavidij, Abdel K. Azab, Rachid Baz, Jacob P. Laubach, Yuji Mishima, Philippe Armand, Nikhil C. Munshi, Frank Basile, Michael Constantine, James Vredenburgh, Adam Boruchov, Pamela Crilley, Patrick M. Henrick, Kalvis T.V. Hornburg, Houry Leblebjian, Stacey Chuma, Kaitlen Reyes, Kimberly NoonanDiane Warren, Robert Schlossman, Claudia Paba-Prada, Kenneth C. Anderson, Edie Weller, Lorenzo Trippa, Kenneth Shain, Paul G. Richardson

Research output: Contribution to journal › Article › peer-review

40 Scopus citations

Sort by
Weight
Alphabetically

Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma

Fingerprint

Medicine & Life Sciences